MHMadhuri Hegde

Madhuri Hegde

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Madhuri Hegde has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Devin Rhodenizer

    Emory Genetics Laboratory, Department of Human Genetics, Emory University, Atlanta, Georgia

    5 shared publications
  • Samya Chakravorty

    21https://ror.org/04k99et05Biocon Bristol Myers Squibb Research and Development Center, Syngene Intl. Ltd., Bengaluru, India

    4 shared publications
  • Shruti Bhide

    Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America

    4 shared publications
  • Arunkanth Ankala

    Emory University School of Medicine

    3 shared publications
  • C. Alexander Valencia

    Emory Genetics Laboratory, Department of Human Genetics, Emory University, Atlanta, Georgia

    3 shared publications
  • Ephrem Chin

    Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia

    3 shared publications

Latest Publications

  • Implementation of Exome Sequencing Assay

    by Samya Chakravorty, Arunkanth Ankala, Madhuri R. Hegde


  • Top Cited Papers
    Open Access

    Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients

    by Babi Ramesh Reddy Nallamilli, Samya Chakravorty, Akanchha Kesari, Alice Tanner, Arunkanth Ankala, Thomas Schneider, Cristina da Silva, Randall Beadling, John J. Alexander, Syed Hussain Askree, et al.

    Objective: Limb‐girdle muscular dystrophies (LGMDs), one of the most heterogeneous neuromuscular disorders (NMDs), involves predominantly proximal‐muscle weakness with >30 genes associated with different subtypes. The clinical‐genetic overlap among subtypes and with other NMDs complicate disease‐subtype identification lengthening diagnostic process, increases overall costs hindering treatment/clinical‐trial recruitment. Currently seven LGMD clinical trials are active but still no gene‐therapy‐related treatment is available. Till‐date no nation‐wide large‐scale LGMD sequencing program was performed. Our objectives were to understand LGMD genetic basis, different subtypes’ relative prevalence across US and investigate underlying disease mechanisms.Methods: A total of 4656 patients with clinically suspected‐LGMD across US were recruited to conduct next‐generation sequencing (NGS)‐based gene‐panel testing during June‐2015 to June‐2017 in CLIA‐CAP‐certified Emory‐Genetics‐Laboratory. Thirty‐five LGMD‐subtypes‐associated or LGMD‐like other NMD‐associated genes were investigated. Main outcomes were diagnostic yield, gene‐variant spectrum, and LGMD subtypes’ prevalence in a large US LGMD‐suspected population.Results: Molecular diagnosis was established in 27% (1259 cases; 95% CI, 26–29%) of the patients with major contributing genes to LGMD phenotypes being: CAPN3(17%), DYSF(16%), FKRP(9%) and ANO5(7%). We observed an increased prevalence of genetically confirmed late‐onset Pompe disease, DNAJB6‐associated LGMD subtype1E and CAPN3‐associated autosomal‐dominant LGMDs. Interestingly, we identified a high prevalence of patients with pathogenic variants in more than one LGMD gene suggesting possible synergistic heterozygosity/digenic/multigenic contribution to disease presentation/progression that needs consideration as a part of diagnostic modality.Interpretation: Overall, this study has improved our understanding of the relative prevalence of different LGMD subtypes, their respective genetic etiology, and the changing paradigm of their inheritance modes and novel mechanisms that will allow for improved timely treatment, management, and enrolment of molecularly diagnosed individuals in clinical trials.


  • Inferring the effect of genomic variation in the new era of genomics

    by Samya Chakravorty, Madhu Ri Hegde

    Accurate and detailed understanding of the effects of variants in the coding and non‐coding regions of the genome is the next big challenge in the new genomic era of personalized medicine, especially to tackle newer findings of genetic and phenotypic heterogeneity of diseases. This is necessary to resolve the gene‐variant‐disease relationship, the pathogenic variant spectrum of genes, pathogenic variants with variable clinical consequences, and multi‐loci diseases. In turn, this will facilitate patient recruitment for relevant clinical trials. In this review, we describe the trends in research at the intersection of basic and clinical genomics aiming to a) overcome molecular diagnostic challenges and increase the clinical utility of next‐generation sequencing (NGS) platforms, b) elucidate variants associated with disease, c) determine overall genomic complexity including epistasis, complex inheritance patterns such as “synergistic heterozygosity”, digenic/multigenic inheritance, modifier effect, and rare variant load. We describe the newly emerging field of integrated functional genomics, in vivo or in vitro large‐scale functional approaches, statistical bioinformatics algorithms that support NGS genomics data to interpret variants for timely clinical diagnostics and disease management. Thus facilitating the discovery of new therapeutic or biomarker options, and their roles in the future of personalized medicine. This article is protected by copyright. All rights reserved


  • Open Access

    Gene and Variant Annotation for Mendelian Disorders in the Era of Advanced Sequencing Technologies

    by Samya Chakravorty, Madhuri Hegde

    Comprehensive annotations of genetic and noncoding regions and corresponding accurate variant classification for Mendelian diseases are the next big challenge in the new genomic era of personalized medicine. Progress in the development of faster and more accurate pipelines for genome annotation and variant classification will lead to the discovery of more novel disease associations and candidate therapeutic targets. This ultimately will facilitate better patient recruitment in clinical trials. In this review, we describe the trends in research at the intersection of basic and clinical genomics that aims to increase understanding of overall genomic complexity, complex inheritance patterns of disease, and patient-phenotype-specific genomic associations. We describe the emerging field of translational functional genomics, which integrates other functional “-omics” approaches that support next-generation sequencing genomic data in order to facilitate personalized diagnostics, disease management, biomarker discovery, and medicine. We also discuss the utility of this integrated approach for diagnostic clinics and medical databases and its role in the future of personalized medicine.


  • Development and Validation of Clinical Whole-Exome and Whole-Genome Sequencing for Detection of Germline Variants in Inherited Disease

    by Madhuri Hegde, Avni Santani, Rong Mao, Andrea Ferreira-Gonzalez, Karen E. Weck, Karl V. Voelkerding

    Context.—: With the decrease in the cost of sequencing, the clinical testing paradigm has shifted from single gene to gene panel and now whole-exome and whole-genome sequencing. Clinical laboratories are rapidly implementing next-generation sequencing–based whole-exome and whole-genome sequencing. Because a large number of targets are covered by whole-exome and whole-genome sequencing, it is critical that a laboratory perform appropriate validation studies, develop a quality assurance and quality control program, and participate in proficiency testing. Objective.—: To provide recommendations for whole-exome and whole-genome sequencing assay design, validation, and implementation for the detection of germline variants associated in inherited disorders. Data Sources.—: An example of trio sequencing, filtration and annotation of variants, and phenotypic consideration to arrive at clinical diagnosis is discussed. Conclusions.—: It is critical that clinical laboratories planning to implement whole-exome and whole-genome sequencing design and validate the assay to specifications and ensure adequate performance prior to implementation. Test design specifications, including variant filtering and annotation, phenotypic consideration, guidance on consenting options, and reporting of incidental findings, are provided. These are important steps a laboratory must take to validate and implement whole-exome and whole-genome sequencing in a clinical setting for germline variants in inherited disorders.


  • Reassessment of Genomic Sequence Variation to Harmonize Interpretation for Personalized Medicine

    by Kathryn B. Garber, Lisa M. Vincent, John J. Alexander, Lora J.H. Bean, Sherri Bale, Madhuri Hegde


  • Regulating whole exome sequencing as a diagnostic test

    by Valentina Lapin, Lindsey C. Mighion, Cristina P. da Silva, Ymkje Cuperus, Lora J. H. Bean, Madhuri R. Hegde

    In the last decade, there has been a flood of new technology in the sequencing arena. The onset of next-generation sequencing (NGS) technology has resulted in the vast increase in genetic diagnostic testing available to the ordering physician. Whole exome sequencing (WES) has become available as a diagnostic test performed in certified clinical laboratories. This has led to increased presence in the diagnostic marketplace, increased consumer awareness, and the question has been raised by various stakeholders to whether there is sufficient stringent regulation of WES and other NGS-based tests. We discuss the various WES services currently available in the marketplace, current regulation of WES as a laboratory developed test, the proposed FDA involvement in its oversight as well as the response of various laboratory groups that provide these diagnostic services. Overall, a rigorous process oversight and assessment of inter-lab reproducibility is strongly warranted for WES as it is used as a diagnostic test, but regulation should be mindful of the excessive administrative burden on academic and smaller diagnostic laboratories.


  • Open Access

    Gene Variant Databases and Sharing: Creating a Global Genomic Variant Database for Personalized Medicine

    by Lora J.H. Bean, Madhuri R. Hegde

    Revolutionary changes in sequencing technology and the desire to develop therapeutics for rare diseases have led to the generation of an enormous amount of genomic data in the last 5 years. Large‐scale sequencing done in both research and diagnostic laboratories has linked many new genes to rare diseases, but has also generated a number of variants that we cannot interpret today. It is clear that we remain a long way from a complete understanding of the genomic variation in the human genome and its association with human health and disease. Recent studies identified susceptibility markers to infectious diseases and also the contribution of rare variants to complex diseases in different populations. The sequencing revolution has also led to the creation of a large number of databases that act as “keepers” of data, and in many cases give an interpretation of the effect of the variant. This interpretation is based on reports in the literature, prediction models, and in some cases is accompanied by functional evidence. As we move toward the practice of genomic medicine, and consider its place in “personalized medicine,” it is time to ask ourselves how we can aggregate this wealth of data into a single database for multiple users with different goals.


  • Congenital Disorders of Glycosylation

    by Melanie A. Jones, Madhuri R. Hegde